Medicine in 50 Years: Repair Instead of Treatment? (2076)

How well can the medicine of 2076 be predicted? A look back helps to put things into perspective: in 1976, hospitals did not yet have magnetic resonance imaging, HIV was unknown, stomach ulcers were thought to be caused by stress and acid, and the first laparoscopic removal of the gallbladder would not take place until 1985 in Böblingen. Much of what is taken for granted today was unimaginable then. With the same humility, we venture a look ahead.

About this series: “The Future of Medicine” looks ahead 5, 10, 15, 25, 50 and 100 years. This part describes possibilities and lines of thought, not forecasts. This version: October 2026.

Possibility 1: replacing lost cells

Many serious diseases are caused by the death of certain cells: nerve cells in Parkinson’s disease, heart muscle cells after a heart attack, insulin-producing cells in type 1 diabetes. Regenerative medicine attempts to recreate such cells from stem cells and replace them. In 2025, two research groups reported in Nature on early clinical trials in which stem cell-derived nerve cells were implanted in people with Parkinson’s disease – with initial evidence of safety and possible efficacy.

In 50 years, the replacement of damaged tissue could be routine for some diseases – ideally with cells from the patient’s own body that do not trigger rejection.

Possibility 2: interventions in the genome – and their limits

Gene editing in somatic cells is already an approved therapy. In 50 years, it could be so precise and safe that many inherited diseases are treatable early in life. Far more controversial are changes to egg or sperm cells or embryos that would be passed on to offspring. Following the scandal surrounding genetically modified babies in China in 2018, professional societies worldwide have warned against such interventions. In Germany, they are prohibited by the Embryo Protection Act. Whether and under what conditions such interventions should ever be permitted is not a technical question but a societal one.

Possibility 3: continuous, invisible health monitoring

Instead of individual measurements at the doctor’s practice, sensors in everyday life – in clothing, implants or the bathroom – could continuously record health data. AI systems would detect changes before symptoms arise. This could identify many diseases at a very early, readily treatable stage. At the same time, it raises questions: who has access to this data? How much monitoring do people want? And how should incidental findings that would never have caused symptoms be handled?

Possibility 4: AI as stand-alone diagnostics

Today, AI supports professionals. In 50 years, parts of diagnostics – such as the evaluation of standard images or laboratory trends – could be fully automated, with human oversight for unclear cases. Medicine would then have to clarify anew who bears responsibility, how errors are detected and how to train doctors who are supposed to supervise machines whose work they no longer do themselves every day.

What is likely to stay the same

• Infections: new pathogens and resistance will still challenge medicine in 2076. The COVID-19 pandemic showed how quickly the healthcare system must then change.
• Lifestyle and environment: diet, exercise, sleep, social relationships and clean air and water will continue to determine much of our health.
• The human need for support: illness is not just a biological problem. Conversation, trust and comfort remain part of good medicine.

The guiding question for 2076

The more medicine can do, the more important the question of what it should do becomes. The boundaries between healing, enhancement and optimisation of human beings are fluid. These decisions should not be made by technology and markets alone, but in open public debate.

How we will know which direction things are taking

• Results of later-phase trials of cell replacement therapies for Parkinson’s disease and diabetes
• International rules on heritable genome editing
• First approvals of fully autonomous AI diagnostics in the EU

Note: This article describes possible developments based on current knowledge. It is not a prediction and does not constitute medical advice.

Updates

• October 2026: first version

Sources

• Tabar V et al.: Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease. Nature 2025
• Sawamoto N et al.: Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease. Nature 2025
• Pharmazeutische Zeitung: Sichere Stammzelltherapie bei Parkinson möglich (April 2025)
• Embryonenschutzgesetz (ESchG), § 5 Künstliche Veränderung menschlicher Keimbahnzellen
• International Commission on the Clinical Use of Human Germline Genome Editing: Heritable Human Genome Editing. National Academies Press 2020